Publication:
Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.

No Thumbnail Available

Date

2019-02-21

Authors

Alten, Rieke
Mariette, Xavier
Lorenz, Hanns-Martin
Nüßlein, Hubert
Galeazzi, Mauro
Navarro, Federico
Chartier, Melanie
Heitzmann, Julia
Poncet, Coralie
Rauch, Christiane

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Evaluate abatacept retention over 2 years in the AbataCepT In rOutiNe clinical practice (ACTION) study. ACTION was an international, observational study of patients with moderate-to-severe rheumatoid arthritis (RA) who initiated intravenous abatacept. Crude abatacept retention rates over 2 years were estimated using Kaplan-Meier analyses in biologic-naive and -failure patients. Clinically relevant risk factors and significant prognostic factors for retention were evaluated using a Cox proportional hazards multivariable model. Overall, 2350/2364 enrolled patients were evaluable; 673 (28.6%) were biologic naive and 1677 (71.4%) had prior biologic failure (1 biologic, 728/1677 [43.4%]; ≥ 2 biologics, 949/1677 [56.6%]). Abatacept retention rate (95% confidence interval [CI]) at 2 years was 47.9% (45.7, 50.0): 54.5% (50.4, 58.3) for biologic-naive vs 45.2% (42.7, 47.7) for biologic-failure patients (log-rank P  Abatacept initiation as earlier vs later line of therapy in RA may achieve higher 2-year retention rates. RF and anti-CCP seropositivity could predict increased abatacept retention, irrespective of treatment line. NCT02109666.

Description

MeSH Terms

Abatacept
Adrenal Cortex Hormones
Aged
Antirheumatic Agents
Arthritis, Rheumatoid
Cohort Studies
Drug Therapy, Combination
Female
Humans
Internationality
Kaplan-Meier Estimate
Male
Methotrexate
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Rheumatoid Factor
Treatment Outcome

DeCS Terms

CIE Terms

Keywords

Biologic, Efficacy, Predictor, Remission, Rheumatoid arthritis

Citation